Over the last few days, the US FDA said it was phasing out animal testing.
Instead, the agency will push for the “development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods. The new approach is designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation, lowering research and development (R&D) costs, and ultimately, drug prices,” they said.
That will be replaced by a range of approaches, including AI-based computational models of toxicity and cell lines and organoid toxicity testing in a lab setting.
So, it came as no big surprise that AI-driven biotech and health tech firms surged.
Here are just a few you may want to consider buying.
Recursion Pharma (SYM: RXRX)
At just $5.50, RXRX is a bargain.
Unlocking the future of biotech with artificial intelligence-powered drug discovery, Recursion Pharmaceuticals is a clinical stage TechBio company decoding biology to industrialize drug discovery – with backing from Nvidia.
What’s most exciting is the company is using generative artificial intelligence to design, synthesize and test novel molecules for efficacy, selectivity, safety and bioavailability.
Enabling the company’s mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. The company leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias.
Schrodinger (SYM: SDGR)
We can also look at Schrodinger, whose AI-powered software technology uses physics-based modeling and machine learning (ML) algorithms to help companies identify which molecules can help treat specific ailments.
Better, its programs can help predict behavior of molecules and possible outcomes. And, it even allows for faster and cheaper discoveries of novel molecules, with a higher rate of success than traditional research methods.
It’s so fast the company’s platform can evaluate molecules in just hours, rather than weeks in a lab. Plus, the software can look at billions of molecules in a single day. Meanwhile, a typical lab would be lucky to look at a thousand inside of a year.
While AI-driven biotech stocks are already gaining momentum, a major announcement by President Trump could send them — and the entire sector — soaring even higher.
Trump Bombshell to Hit By April 30th?
If you have any money in AI stocks, pay attention because…
According to Louis Navellier, the legendary investor who picked Nvidia before shares exploded as high as 3,423%…
Before April 30th, President Trump could make a shocking AI announcement…
Sending these stocks exploding higher.
